Voyager Therapeutics EPS - Earnings per Share 2014-2022 | VYGR

Voyager Therapeutics eps - earnings per share from 2014 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Voyager Therapeutics Annual EPS
2021 $-1.89
2020 $0.98
2019 $-1.21
2018 $-2.75
2017 $-2.64
2016 $-1.59
2015 $-9.14
2014 $-27.83
2013 $-1,629.68
Voyager Therapeutics Quarterly EPS
2022-06-30 $-0.50
2022-03-31 $-0.56
2021-12-31 $0.16
2021-09-30 $-0.67
2021-06-30 $-0.80
2021-03-31 $-0.58
2020-12-31 $-0.40
2020-09-30 $2.27
2020-06-30 $-0.23
2020-03-31 $-0.66
2019-12-31 $-0.28
2019-09-30 $-0.41
2019-06-30 $0.29
2019-03-31 $-0.81
2018-12-31 $-0.69
2018-09-30 $-0.63
2018-06-30 $-0.80
2018-03-31 $-0.63
2017-12-31 $-0.37
2017-09-30 $-0.89
2017-06-30 $-0.73
2017-03-31 $-0.65
2016-12-31 $-0.58
2016-09-30 $-0.35
2016-06-30 $-0.37
2016-03-31 $-0.29
2015-12-31 $17.84
2015-09-30 $-5.25
2015-06-30 $-5.94
2015-03-31 $-15.79
2014-12-31 $-6.58
2014-09-30 $-6.45
2014-06-30 $-8.11
2014-03-31 $-6.93
2013-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.225B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $159.205B 9.66
GSK (GSK) United Kingdom $70.569B 8.47
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $10.911B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $10.582B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.792B 0.00
Arcus Biosciences (RCUS) United States $1.905B 37.18
Myovant Sciences (MYOV) United Kingdom $1.738B 0.00
Emergent Biosolutions (EBS) United States $1.418B 8.22
Zymeworks (ZYME) Canada $0.370B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.094B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00